PEPG Investor Notice: Robbins LLP Reminds Investors of the Class Action Lawsuit Against PepGen Inc.

Group 1 - A class action has been filed on behalf of investors who purchased PepGen Inc. (NASDAQ:PEPG) securities between March 7, 2024, and March 3, 2025 [1] - PepGen is a clinical-stage biotechnology company focused on developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases, with its lead product candidate being PGN-EDO51 for Duchenne muscular dystrophy (DMD) [1] - Allegations against PepGen include misleading investors about the effectiveness and safety of PGN-EDO51, deficiencies in the CONNECT2 study, and overstated clinical and commercial prospects [2] Group 2 - On January 29, 2025, PepGen reported safety concerns in the CONNECT1 study and FDA concerns regarding the CONNECT2 study, leading to a stock price drop of $0.40 per share (21.74%) [3] - Following a press release on March 4, 2025, announcing a voluntary pause of the CONNECT2 study, PepGen's stock price fell by $0.53 per share (18.86%) [4] - Shareholders interested in participating in the class action must file a motion for lead plaintiff by August 8, 2025 [5]